Lyka Labs Limited

NSE LYKALABS.NS

Lyka Labs Limited Return on Assets (ROA) for the year ending March 31, 2024: -1.59%

Lyka Labs Limited Return on Assets (ROA) is -1.59% for the year ending March 31, 2024, a 81.70% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Lyka Labs Limited Return on Assets (ROA) for the year ending March 31, 2023 was -8.68%, a -141.31% change year over year.
Lyka Labs Limited Return on Assets (ROA) for the year ending March 31, 2022 was 21.01%, a 495.65% change year over year.
Lyka Labs Limited Return on Assets (ROA) for the year ending March 31, 2021 was -5.31%, a 83.06% change year over year.
Lyka Labs Limited Return on Assets (ROA) for the year ending March 31, 2020 was -31.34%, a -1,127.52% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NSE: LYKALABS.NS

Lyka Labs Limited

CEO	Mr. Kunal Narendra Gandhi
IPO Date	Jan. 1, 1996
Location	India
Headquarters	Spencer Building
Employees	423
Sector	Healthcare
Industries Drugstores & Retail Pharmacies Clinical Trials Cosmetics Personal Care Pharmaceuticals

Description

Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.

Key trends

Past 5 years